US EditionHeidelberg Pharma Reports Promising Clinical Data for Multiple Myeloma Treatment HDP-101
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Heidelberg Pharma Reports Promising Clinical Data for Multiple Myeloma Treatment HDP-101
Heidelberg Pharma AG will present new clinical data from its ongoing Phase I/IIa study of HDP-101, an anti-BCMA antibody-drug conjugate for relapsed or refractory multiple myeloma, at the 16th Annual World ADC Congress in San Diego. The data show objective responses and promising anti-tumor activity observed in several patients across multiple cohorts, reinforcing the therapeutic potential and safety profile of the investigational treatment. Pro…
Optimum Strategic Communications
NewMediaWireHeidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
Objective responses and promising anti-tumor activity observed in several patients across multiple cohorts in the ongoing Phase I/IIa clinical trial Data reinforces the therapeutic potential and safety profile of HDP-101 in relapsed or refractory multiple myeloma. R&D Webinar to be hosted on 11 November 2025 at 05:00 pm CET (08:00 am PST) Ladenburg, Germany, 3 […] The post Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
